This table presents recent patent oppositions filed by Shire Human Genetic Therapies, Inc. against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP2708559Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 21, 2018
EP2708558Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 20, 2018
EP2552955Antibodies With Modified Affinity To Fcrn That Promote Antigen ClearanceCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 5, 2018

The following table provides an overview of the latest patents of Shire Human Genetic Therapies, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2858679Jun 5, 2024Pulmonary Delivery Of Mrna To Non-Lung Target Cells1
EP3626258Aug 4, 2021Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase1
EP2970456May 19, 2021Methods And Compositions For Delivering Mrna Coded Antibodies4
EP3103469Dec 9, 2020Cns Delivery Of Therapeutic Agents1
EP3134506Aug 7, 2019Methods For Purification Of Messenger Rna2
EP3060303Nov 14, 2018Mrna Therapy For Argininosuccinate Synthetase Deficiency1
EP3122878Oct 24, 2018Mrna Therapy For The Treatment Of Ocular Diseases1
EP2867245Sep 12, 2018Purification Of Iduronate-2-Sulfatase1
EP2506857Feb 14, 2018Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases2